Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY2382770 in diabetic kidney disease
2010-020404-29Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis, chronic kidney disease (CKD), diabetes mellitus type 1 (T1D) and 1 more comparing LY2382770 with Placebo (2 arms). Primary endpoint: Change in serum creatinine from baseline. Started Jan 2011; status: terminated.
02
Drugs
LY2382770
03
Conditions
diabetic glomerulosclerosischronic kidney disease (CKD)diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-020404-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020404-29.